



Frequently Asked Questions

Document type: training material File name: ERKReg_FAQ_updated_26.02.24 Produced by: ERKNet-The European rare Kidney Disease Reference Network Release date: 21/02/2024



Funded by the European Union



Table of Content

1.	What is ERKReg?	
2.	Who can see the data I enter in the registry?	
3.	Where are the data stored?	
4.	For how long will data be kept in the ERKReg database?	
5.	Can I download the data of my centre?	
6.	Which browser is best to use ERKReg?	
7.	How to get started with ERKReg?	
8.	How can I request access to ERKReg?	
9.	How can I log in?	
10.	Is patient consent mandatory for enrolling patients in the ERKReg?	
11.	How can I enroll a patient into ERKReg?	
12.	How do I know the ID code of my patient?	
13.	Do all ERKReg patients have to be registered in the sub-registries?	
14.	What date should I indicate in the box 'date of first symptoms'?	
15.	Can I change the DOB of a patient if it would incorrectly be entered and saved?	
16.	How can I choose the "primary renal diagnosis"?	
17.	What should I do when the renal diagnosis of a patient has not been established yet?	
18.	How do I know which is the primary and which is the secondary renal diagnosis?	
19.	How do I know when the diagnosis was confirmed?	/
20.	How do I know how the diagnosis was established?	
Clin	ical history:	
Pos	itive family history:	
	ical examination (or physical examination)	
	ilomerulopathiesiubulopathiesiubulopathies	
	MA	
Ima	ging	1
Ger	netic screening	1
21.	How can I choose between the different Methods of genetic diagnostics?	_ 1
Ind	ividual gene testing	1
NG	S panel screening	1
	me sequencing	
22.	How do I enter the genetic results?	_ 1
23.	What to do if my gene is not in the dropdown list	_ 1
24.	What should I indicate when the genetic diagnostic has not been performed?	1



25.	How to enter CAKUT patient?	13
26.	How to enter syndromic CAKUT patients	13
27.	How do I choose the date of the "initial visit"?	14
28.	How do I know when the next visit is due?	14
29.	Why is "next visit due" highlighted in different colors?	14
30.	When do I have to terminate a patient and how can I do it?	15
31.	What is the medication and therapy database?	15
32.	What "ID number" should I indicate in the informed consent?	15
33.	What is the Key Performance Indicator (KPI) Monitoring System	16
34.	How can I contact the IT support?	16



1. What is ERKReg?

The ERKNet Registry, also known as ERKReg, is a secure web-based application which has four major aims:

- (i) to generate epidemiological information,
- (ii) to identify current patient cohort for clinical research,
- (iii) to explore diagnostic and therapeutic management practices and
- (iv) to monitor treatment performance and patient's outcomes.

Moreover, the registry allows to integrate detailed disease-specific registries as extensions to the core database.

2. Who can see the data I enter in the registry?

Are my data visible to the investigators of other Centres?

Access of authorized users to the registry is controlled by assignment of a secure, individualized password. A hierarchical access authorization system is implemented with super-administrator, administrator, sub-administrator andcentre user levels.

Project Management Team ('super- administrator')	This group will have access to the global database.
Sub-Registry Leads ('sub-administrator')	This group will have access to all data in the associated sub- registry.
Center users	This group will have access to their own center's data.
Investigators	This group may propose analyses of registry data by submitting an Analysis Request Form for review and approval by the Data access committee.

The data entered will only be visible to the investigators of your own centre and will not be shared with other users of the registry, except in aggregated format for benchmarking purposes. Sub-administrators are authorized download data excerpts from patients with the disease(s) of their interest.

3. Where are the data stored?

The data are stored on a commercial server in Germany, unaccessible to non-authorised personnelor entities. Regular back-ups are made. These back-ups are kept in a secured location. They guarantee the protection of (identifiable) data and the security of all information.

4. For how long will data be kept in the ERKReg database?

The data will be kept in the database for at least 15 years. Data will not be destroyed without permission of the user.



5. Can I download the data of my centre?

The lead investigator of the centre is authorized to download at any time all data of the patients tagged as participating in the Registry/Affiliated Registry and use these data without restrictions for analytical purposes.

6. Which browser is best to use ERKReg?

To maximise your experience with ERKReg, users are highly advised to use modern web-browsers. Recent versions of Google Chrome, Mozilla Firefox and Safari provide the best user experience. Microsoft Edge and Internet Explorer support ERKReg.

7. How to get started with ERKReg?

- Submit the patient informed constent form to your data protection office/ ethics board for local approval
- ✓ Multilingual research-oriented ICF provided by the coordination office
- ✓ Supportive infomation available from the coordination office
- ✓ Obtain the patient consent in your center
- ✓ Train your doctors in the ambulance and ward in proper informing the patients about ERKReg → hand out the patient information flyer
- Elaborate an internal system how to track the patients and their next visit
- ✓ Identify a staff member in charge for the data entries into the online registry
- ✓ Keep a local list of the patient's identity (e.g. excel list with ERKReg pseudonym, name, date of birth)
- ✓ Contact person for centre queries
- Review your centre performance in patient management Continuously online in centre dashboard Upon receiving the bi-annual KPI reports

8. How can I request access to ERKReg?

To be able to start, the first requirement for the user is to request a login. For this purpose, pleasesend an e-mail request to the ERKReg Support Team: <u>erkreg@erknet.org</u>

9. How can I log in?

The application can be accessed through web-browsers. For best experience, make sure you are using a supported browser. ERKReg is supported to its full potentials on Google Chrome, MozillaFirefox and Safari, preferably latest version. You can access the registry by the ERKNet page webpage by clicking on <u>www.erkreg.org</u>



The European Rare Kidney Disease Reference Network

When you have an ERKReg login account (which can be used to access multiple ERKNet services), enter username and the password provided by the help desk member and click on the button "Login".

10. Is patient consent mandatory for enrolling patients in the ERKReg?

Yes, all patients must give at least a consent for data use in ERN registries and databases that willbe recorded by ticking a checkbox indicating the minimum has been collected. The consent formscan be obtained by the ERKNet Central Office.

11. How can I enroll a patient into ERKReg?

To enroll a new patient from your centre, please click on "Data entry".

12. How do I know the ID code of my patient?

The patient ID is automatically generated by the system after saving the data. You can see the patient-ID on the left of the menu. We recommend generating a local Excel document with the Name, Surname, date of birth, date of informed consent, together with the ERKReg patient ID. Thiskey document should only be stored on a save hospital server and only be shared among the local users of the registry.

13. Do all ERKReg patients have to be registered in the sub-registries?

No, only patients with a rare kidney disease for which a sub-registry has been established can be entered into these affiliated registries by selecting the corresponding sub-registry in the basic data form.

Patient-ID	Will be generated after saving
Basic data entry not completed!	
Patient also registered for:	
dRTA Subregistry	
Italian Alport Subregistry	
Childhood-onset SLE Subregistry	
Cystinuria Subregistry (Eurocys)	
Bartter/Gitelman Subregistry	
esCapeKD Subregistry and Cohort Study	
CompCure C3G/MPGN Subregistry and Cohort St	udy 🗌

14. What date should I indicate in the box 'date of first symptoms'?

The date of first symptoms onset is usually related to the underlying disease. Sometimes the early symptoms of a rare kidney disease coincide with the first presentation at the hospital. Sometimes the first symptoms may appear long before the patient sees the doctor. For most of the CAKUT, the diagnosis can already be made during the pregnancy, as signs can be detected by ultrasound (e.g. oligohydramnios in the case of PUV). In this case, it is possible to indicate a date before birth as "date of the first symptom". If the date of first symptoms is not specified in the medical records, we ask the user



to carefully read patients' medical history and assess when the symptoms started. If it is not possible to trace the date, please leave the box blank.

Basic data	
Sex	•
Date of birth	(mm/yyyy)
Ethnicity	•
Date of first symptoms (leave field empty if unknown)	(mm/yyyy)
Date of first presentation to center	(dd/mm/yyyy)

15. Can I change the DOB of a patient if it would incorrectly be entered and saved?

Yes, no problem! You can change this at any moment. Watch out: If the date of birth is subsequently changed because it may have been entered incorrectly, all visits must be saved again so that the SDS value for height and BMI for weight can be recalculated.

16. How can I choose the "primary renal diagnosis"?

Before registering a patient, we recommend checking the "Renal Orphacode list" (available in Downloads menu). The list contains all the kidney diseases in the registry to clarify the user which diseases can be entered and which not.

In the data entry menu, the "Primary renal diagnosis" can be chosen through 4 different searchbars:

-"Select diagnosis": the search is made along the Orphanet diagnosis tree, choosing in hierarchicalorder the disease groups down to the entity of choice.

-"Diagnosis by gene": Type in the search bar the name of the mutated gene that caused the disease. The disease(s) associated with the gene will pop up.

- "Enter ORPHA code": Type the Orphanet disease code in the search bar.

- "Search diagnosis name": Enter at least the first 4 letters of the disease name into the search bar.

Patient-ID	Will be generated after saving	Primary renal diagnosis	(OC: 0)
Basic data entry not completed!		Select diagnosis OR Diagnosis by gene OR	haCode
Patient also registered for: dRTA Registry		Does the patient have a second renal diagnosis?	■ If two renal diagnoses are ■ recorded, the one more
Italian Alport Registry Childhood-onset SLE Registry Cystinuria Registry (Eurocys)		Diagnostic survey When was the diagnosis considered confirmed?	relevant to the clinical course should be choosen
TEST Sub-Registry Center unit Note: Center unit is not changeable after saving. Please enter with carel	(under construction - do not check yet!)	Which methods were used to establish the diagnosis? (Tick all that apply) (¹) Please check even if results negative or pend	Clinical history Positive family history Clinical examination Biochemical evaluation munological evaluation
ERKNet Registry Date of informed consent Consent to data being shared for clinical care Consent to coded data being included in one or mo ERN database or registry Consent to being contacted about research project	CAROT cases, the date of	Date of genetic screening, kidney biopsy, imaging abnormal lab values	Hemitological evaluation Hematological evaluation Imaging Kidney biopsy Skin biopsy Genetic screening ⁽¹⁾ Other methodologies
Basic data	entered	Completed	Check this box for full data validation and completion of basic data! Otherwise proceeding with visit data is not possible.
Date of birth Ethnicity	(mm/yyyy)	Save	Return to patient list
Date of first signs or symptoms (leave field empty if unknown) Date of first presentation to center	(mm/yyyy) (dd/mm/yyyy) First seen in you	r contro	
Renal diagnosis established?	Yes v		



17. What should I do when the renal diagnosis of a patient has not been established yet?

If the kidney diagnosis has not been established, mark "no" in the respective field of the basic entry menu. You can come back and change this entry and at additional information at any time once therenal diagnosis has been established.

18. How do I know which is the primary and which is the secondary renal diagnosis?

Usually, the primary diagnosis is the one confirmed by genetics. If genetics has not been performed, the primary diagnosis is generally stated first in the patient's letter. In case it is still unclear, which is the main diagnosis, please contact the referring doctor of your ERKNet Centre for clarification.

Renal diagnosis established?	Yes
Primary renal diagnosis	(OC: 0)
Select diagnosis OR Diagnosis by gene OR	Enter OrphaCode OR Search diagnosis name
Does the patient have a second renal diagnosis?	No 💌

19. How do I know when the diagnosis was confirmed?

This depends on the type of disease: sometimes it requires a genetic test or a kidney biopsy result, in other cases the physician in charge can make a diagnosis based on ultrasound or on clinicalgrounds. To help in a general way, we can state that a glomerulopathy's diagnosis is usually confirmed by genetics or less frequently by biopsy results. For tubulopathies, ciliopathies and metabolic nephropathies, the diagnosis is confirmed by genetics. For the thrombotic microangiopathies, the diagnosis is confirmed by genetics results. For CAKUT by cystouretrography or radiological examination. Sometimes, it takes years before the genetic cause is found; in these cases, it makes sense to choose an earlier date with different criteria.

It is always advisable to ask the referring physician of the ERKNet Centre for support in case of doubt.

Diagnostic survey	
When was the diagnosis considered confirmed?	(dd/mm/yyyy)
How was the diagnosis established?	Clinical history
(Tick all that apply)	Positive family history
⁽¹⁾ Please check even if results negative or pending	Clinical examination
	Biochemical evaluation
	Immunological evaluation
	Hematological evaluation
	Imaging
	Kidney biopsy
	Skin biopsy
	Genetic screening ⁽¹⁾
	Other methodologies



20. How do I know how the diagnosis was established?

Diagnostic survey				
When was the diagnosis considered confirmed?	(dd/mm/yyyy)			
How was the diagnosis established?	Clinical history			
(Tick all that apply)	Positive family history			
⁽¹⁾ Please check even if results negative or pending	Clinical examination			
Please check even in results negative or pending	Biochemical evaluation			
	Immunological evaluation			
	Hematological evaluation			
	Imaging			
	Kidney biopsy			
	Skin biopsy			
	Genetic screening ⁽¹⁾			
	Other methodologies			

Medical diagnosis is the process of determining which disease or condition explains a person's symptoms and signs. The information required for diagnosis is typically collected from a history and physical examination of the person seeking medical care. Often, one or more diagnostic procedures, such as medical tests, are also done during the process. Here below you will find listed a number of variables that could help you to establish a diagnose.

<u>Clinical history:</u> a narrative or record of past events and circumstances that are or may be relevant to a patient's current state of health. For instance, a patient with Alport disease could tell that he may could experience the presence of blood in urine.

<u>Positive family history</u>: A family medical history can identify people with a higher-than-usual chance of having common diseases. These disorders are influenced by a combination of genetic factors, environmental conditions, and lifestyle choices. For instance, the Autosomal dominant polycystic kidney disease (ADPKD) is an inherited condition. A patient with ADPKD could have one or more relatives who are affected by the same disease.

<u>Clinical examination (or physical examination)</u>: helps the medical doctor to determine the general status of patient's health. The exam also gives the chance to talk to patients about any ongoing pain or symptoms that they are experiencing. For instance, signs and symptoms of nephrotic syndrome include: Severe swelling (edema), particularly around the eyes and in ankles and feet. Weight gain due to fluid retention.

An <u>evaluation of biochemical, hematological and immunological parameters</u> helps the doctor to establish a diagnosis.

For Biochemical we intend an electrolyte panel, also known as a serum electrolyte test, is a blood test that measures levels of the body's main electrolytes. This could be important in a Tubulopathy where we expect variation of the electrolytes in blood and urine (Na, K, Ca, Mg, etc.). We intend also all the other lab test (e.g. LDH, renal function, pancreatic and liver enzymes) that are not hematological or immunological parameters.

Hematological parameters are red blood cell count (RBC), white blood cell count (WBC), platelet count, hemoglobin, hematocrit, mean volume (MCV), etc. For instance, a Hemolytic-uremic syndrome (HUS) is an acute, fulminant disorder characterized by thrombocytopenia (low platelet count) and microangiopathic hemolytic anemia (low RBC).

For Immunologic blood test, are intended any of a group of diagnostic analyses of blood that employ antigens (foreign proteins) and antibodies (immunoglobulins) to detect abnormalities of the immune system. These tests are used for detecting autoimmune disorders. Please take a look here below at the immunological diagnostics it may be requested.



Glomerulopathies:

A	В	с	D	E	F	G	н	1	1	K
Diagnosis	C3 glomerulonephritis	Dense deposit disease	Primary IgA nephropathy (Berger disease)	Immune complex associated membranoproliferative glomerulonephritis, with complement abnormalities	Immune complex associated membranoproliferative glomerulonephritis, not otherwise specified	Membranous nephropathy	Lupus like glomerulopathy ('full house' nephropathy)	Adult-onset Still disease	Buerger disease	Dermatomyositis
Drphacode	329918	93571	9999982	329903	9999975	97560	9999981	829	36258	221
Serum C3	not tested/normal/low	not tested/normal/low	not tested/normal/low	not tested/normal/low	not tested/normal/low	not tested/normal/low	not tested/normal/low			
Serum C4	not tested/normal/low/elevated	not tested/normal/low/elevated		not tested/normal/low/elevated	not tested/normal/low/elevated	not tested/normal/low/elevated	not tested/normal/low/elevated			
Serum IgA			not tested/normal/elevated							
dsDNA							not tested/negative/positive			
ANA				not tested/negative/positive	not tested/negative/positive	not tested/negative/positive	not tested/negative/positive	at tested/negative/posi	t not tested/negative/positive	not tested/negative/positiv
Anti-beta2 Glycoprotein IgC									not tested/negative/positive	
Anti-beta2 Glycoprotein Ig?									not tested/negative/positive	
Lupus anticoagulant									not tested/negative/positive	
Anti-Ro (SSA)										
Anti-RNP										
Anti-phospholipase A2										
Anti-phospholipid/Anti-can	iolipin								not tested/negative/positive	
Anti-CCP										
RF								not tested/negative/posi	t not tested/negative/positive	
ACA									not tested/negative/positive	
cANCA				not tested/negative	not tested/negative					
PANCA				not tested/negative	not tested/negative					
Myeloperoxidase-ANCA										
Antiproteinase 3-ANCA										
PLA2 antibodies						not tested/negative/positive				
C3 nephritis factor CFH autoantibodies	not tested/negative/positive	not tested/negative/positive not tested/negative/positive				not tested/negative				
CFH autoantibodies Anti-scl70	not tested/negative/positive	not tested/negative/positive				not tested/negative				
Anti-sci70 Anti PM-Sci									not tested/negative/positive	
Anti-RNA polymerase III Anti-SM										
Anti-Mi-2										not tested/negative/positiv
Anti-Mi-Z Anti-GBM										not tested/negative/positiv
Cryoglobulin				not tested/negative/positive	not tested/negative/positive					
Anti-Jo-1				nos verveu/nagative/positive	not cerced/mgatweypositive					not tested/negative/positiv

	lean eals		L	M	N	0	Р	Q	n	S		U	
initial control	agnosa	Dermatomyositis				Systemic sclerosis	Systemic Lupus Erytematosus	Pediatric systemic lupus erythematosus	Reynolds syndrome	C3 glomerulopathy secondary to MGRS	glomerulonephritis with monoclonal immune		Immunoglobulin A vasculit
	rphacode	221	93672	732	93568	90291	93552	93552	779	999970		375	761
initial Andrew and all all all all all all all all all al													
N N							not tested/normal/low/elev	ate not tested/normal/low/elevated		n	ot tested/normal/low/elevat	ed	
N Image: set in the set i	DNA						a at tested in continue in a sit	and texted formation for a sition					not tested/norma/elevate
	NA .	not tested (nerstive/positive				not tested (nerstive/nositive			not tested /nemtive/positive				
	nti-beta2 Glycoprotein Ig	(not corcornagion oppositive			not tested/negative/positive				
Air Mini (Air M	nti-beta2 Glycoprotein Igl												
SAME Springer Co. Co. Co. Co. Co. Co. Co. Co. Co. Co.	upus anticoagulant												
	nti-Ro (SSA)												
							not tested/negative/posit	ve not tested/negative/positive					
							not tested (aceptive) and it	not tested (constitution as it is					
	nti-CCP						not testeu/negative/posit	ve not tested/negative/positive					
	F								not tested/negative/positive				
	CA					not tested/negative/positive			not tested/negative/positive				
	ANCA												
	ANCA												
regeneration of the second of	ntiproteinase 3-ANCA											not tested/negative/positive	
	3 nephritis factor												
	FH autoantibodies						not tested/negative/posit	ve not tested/negative/positive					
	nti-scl70								not tested/negative/positive				
	nti PM-Scl												
						not tested/negative/positive			and factor for section for a little				
		not tested (negative (noritive	tested (negative (nor it)						not usted/negative/positive				
operation operation <t< td=""><td>nti-GBM</td><td>not tested/negative/positive</td><td>. testeer, negative, positiv</td><td>~</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>not tested/negative/positive</td><td></td></t<>	nti-GBM	not tested/negative/positive	. testeer, negative, positiv	~								not tested/negative/positive	
A Ø Ø X V Z AA AB prob Gramopore Gramopore Gramopore Gramopore Gramopore Gramopore Gramopore hade 1000 130 270 9104 101 un G 1000 130 270 9104 101 un G N N N N N un G N N N N N N	ryoglobulin								not tested/negative/positive				
general general formageneral (Nergeneral) formageneral (Nergenera) <th< td=""><td>nti-Jo-1</td><td>not tested/negative/positive</td><td>tested/negative/posit t</td><td>ested/negative/pos</td><td>ii: tested/negative/po</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	nti-Jo-1	not tested/negative/positive	tested/negative/posit t	ested/negative/pos	ii: tested/negative/po								
Apparentia functore Name Name Name Apparentia functore Anced 0.00 1.80 7.27 9.12 10.7 In Constructore In Constructore In Constructore In Constructore Anced In Constructore In Constructore <th>Δ</th> <th>W</th> <th>Х</th> <th></th> <th>Y</th> <th>Z</th> <th>AA</th> <th>AB</th> <th></th> <th></th> <th></th> <th></th> <th></th>	Δ	W	Х		Y	Z	AA	AB					
m C1 m (c)		diameter and a state	Parts and We may be		and a set of the set of the set	Barrel Income		Barahan dia ana					
m MA Na Carbonal Series Alexander Series Carbonal Series Carb	iagnosis				copic polyangiitis			Bechet disease					
m MA Na Carbonal Series Alexander Series Carbonal Series Carb		polyangiitis (Wegener)	with polyangiiti			glomerulonephritis	Polyarteritis nodosa						
m m A A A A C decognicity deca decognicity	iagnosis rphacode	polyangiitis (Wegener)	with polyangiiti			glomerulonephritis 93126	Polyarteritis nodosa 767						
Netzel Congenie of a set and ngenie position on testand ngenie position on	rphacode erum C3	polyangiitis (Wegener)	with polyangiiti			glomerulonephritis 93126	Polyarteritis nodosa 767 not tested/normal/low						
Netzel Congenie of a set and ngenie position on testand ngenie position on	rphacode erum C3 erum C4	polyangiitis (Wegener)	with polyangiiti			glomerulonephritis 93126	Polyarteritis nodosa 767 not tested/normal/low						
<pre>send stype:send s</pre>	rphacode erum C3	polyangiitis (Wegener)	with polyangiiti			glomerulonephritis 93126	Polyarteritis nodosa 767 not tested/normal/low						
<pre>s mitemage/mage/mage/mage/mage/mage/mage/mage</pre>	rphacode erum C3 erum C4 erum IgA sDNA NA	polyangiitis (Wegener)	with polyangiiti			glomerulonephritis 93126 not	Polyarteritis nodosa 767 not tested/normal/low tested/normal/low/elevated t tested/negative/positive	117					
king Kog kow kow kow kow kow kow kow kow	ingnosis rphacode erum C3 erum C4 erum IgA sDNA NA NA NA	polyangilitis (Wegener) 900	with polyangiiti			glomerulonephritis 93126 not	Polyarteritis nodosa 767 not tested/normal/low tested/normal/low/elevated t tested/negative/positive not tested/negative/positive ont tested/negative/positive	117 tested/negative/c					
sky biopholex AD peopolex A	rphacode rrum C3 rrum C4 rrum IgA IDNA VA Nti-beta2 Glycoprotein Igd	polyangilitis (Wegener) 900	with polyangiiti			glomerulonephritis 93126 not	Polyarteritis nodosa 767 not tested/normal/low tested/normal/low/elevated t tested/negative/positive not tested/negative/pow oto tot tested/negative/pow	117 tested/negative/ic tested/negative/ic					
perspective per	rphacode erum C3 erum C4 erum IgA sDNA NA	polyangilitis (Wegener) 900	with polyangiiti			gomerulonephritis 93126 not	Polyarteritis nodosa 767 not tested/normal/low tested/normal/low/elevated t tested/negative/low of not tested/negative/low of not tested/negative/low of not tested/negative/low	117 tested/negative/ic tested/negative/ic					
CCC In of tatal/ngative/positive not tatal/ng	Ingnosis rrphacode rrum C3 srum C4 srum [AA SDFAA K4-bat2 Glycoprotein [kg rb-beta2 Glycoprotein [kg upus anticoagulant rb-fab2 SAA) mb-RaP	polyangilitis (Wegener) 900	with polyangiiti			gomerulonephritis 93126 not	Polyarteritis nodosa 767 not tested/normal/low tested/normal/low/elevated t tested/negative/low of not tested/negative/low of not tested/negative/low	117 tested/negative/ic tested/negative/ic					
A category and a c	rphacode srum C3 srum C4 srum C4 sDPA AVA M5-bts2 Glycoprotein (gf apps anticogulant m6-Bo (SSA) m6-Bo (SSA)	polyangilitis (Wegener) 900	with polyangiiti			gomerulonephritis 93126 not	Polyarteritis nodosa 767 not tested/normal/low tested/normal/low/elevated t tested/negative/low of not tested/negative/low of not tested/negative/low	117 tested/negative/ic tested/negative/ic					
A A <td>rrum C3 rrum C4 rrum C4 DDA DDA MA 44 45-bei 24 Dycoprotein by tis-bei 24 Dycoprotein by tis-bei 24 Dycoprotein by tis-bei 25 Dycoprotein by tis-bei</td> <td>polyangilitis (Wegener) 900</td> <td>with polyangiiti</td> <td></td> <td></td> <td>glomerulonephritis 93126 not not</td> <td>Polyateritis nodosa 767 not tested/normai/low/ tested/normai/low/evated ttested/negative/low of not tested/negative/low of not tested/negative/low of tested/negative/low of tested/neg</td> <td>117 tested/negative/ic tested/negative/ic</td> <td></td> <td></td> <td></td> <td></td> <td></td>	rrum C3 rrum C4 rrum C4 DDA DDA MA 44 45-bei 24 Dycoprotein by tis-bei 24 Dycoprotein by tis-bei 24 Dycoprotein by tis-bei 25 Dycoprotein by tis-bei	polyangilitis (Wegener) 900	with polyangiiti			glomerulonephritis 93126 not not	Polyateritis nodosa 767 not tested/normai/low/ tested/normai/low/evated ttested/negative/low of not tested/negative/low of not tested/negative/low of tested/negative/low of tested/neg	117 tested/negative/ic tested/negative/ic					
CA not test/anglundpointe not test/anglundpointe not test/anglundpointe not test/anglundpointe not test/anglundpointe CA not test/anglundpointe not test/anglundpointe not test/anglundpointe not test/anglundpointe Ca not test/anglundpointe not test/anglundpointe not test/anglundpointe not test/anglundpointe Ca not test/anglundpointe not test/anglundpointe not test/anglundpointe not test/anglundpointe Ca not test/anglundpointe not test/anglundpointe not test/anglundpointe not test/anglundpointe Ca not test/anglundpointe not test/anglundpointe not test/anglundpointe not test/anglundpointe Ca not test/anglundpointe not test/anglundpointe not test/anglundpointe not test/anglundpointe Sta Not test/anglundpointe not test/anglundpointe not test/anglundpointe not test/anglundpointe Sta Not test/anglundpointe not test/anglundpointe not test/anglundpointe not test/anglundpointe Sta Not test/anglundpointe Not test/anglundpointe Not test/anglundpointe Not test/anglundpointe Sta Not test/anglundpointe Not test/anglundpointe	Ingnosis phacode ph	polyangilitis (Wegener) 900	with polyangiiti			glomerulonephritis 93126 not not	Polyateritis nodesa 767 not tested/normal/ow tested/normal/ow/levated t tested/negative/positive or tested/negative/positive t tested/negative/positive t tested/negative/positive	117 tested/negative/ic tested/negative/ic					
CA not task/ngatu/opisub not task/ngatu/opisub not task/ngatu/opisub not task/ngatu/opisub not task/ngatu/opisub preduber not task/ngatu/opisub not task/ngatu/opisub not task/ngatu/opisub not task/ngatu/opisub preduber not task/ngatu/opisub not task/ngatu/opisub not task/ngatu/opisub not task/ngatu/opisub preduber not task/ngatu/opisub not task/ngatu/opisub not task/ngatu/opisub not task/ngatu/opisub stash/ngatu/opisub not task/ngatu/opisub not task/	agnosis phacode rum C3 rum C4 DNA A A A A A A A DNA A A DNA A A DNA A A DNA A A DNA A A DNA A A A	polyangilitis (Wegener) 900	with polyangiiti			glomerulonephritis 93126 not not	Polyateritis nodesa 767 not tested/normal/ow tested/normal/ow/levated t tested/negative/positive or tested/negative/positive t tested/negative/positive t tested/negative/positive	117 tested/negative/ic tested/negative/ic					
processes processes processes processes not tastad/negative/positive not tastad/negative/positive not tastad/negative/positive septide processes processes processes	Ingnosis rphacode server GA server BA DDA NA NA NA NA NA NA NA NA NA N	polympilia (Wegner)	with polyangiti	5 	727	giomerukonghiriti 93126 not not not not not not not not not not	Polyateritis nodesa 767 not tested/normal/ow tested/normal/ow/levated t tested/negative/positive or tested/negative/positive t tested/negative/positive t tested/negative/positive	117 tested/negative/ic tested/negative/ic					
2 artiscalar separate Tables separate	sgroots phacode num C3 num C3 num C4 bit2 DitA bit2 bit2 Cipcontain bit bit2 cipcontain bit2 cipco	polymetilik (Wegner) 900 not tisted/ngtitv/politike not tisted/ngtitv/politike	with polyangiti	boiltive not teste	727 d/negative/positive	generolonsphrifa 93126 not not not not teste/ngenye/poster not teste/ngenye/poster not	Polyateritis nodosa 767 not tested/normal/low/sector/ tested/normal/low/sector/ tested/normal/low/sector/ tested/negative/positive on tested/negative/positive t tested/negative/positive	117 tested/negative/ic tested/negative/ic					
separation fairs separation f	Ingnosis Inghacode arrum C3 arrum C4 DRA NA NA NA NA NA NA NA NA NA N	polymetilik (Wegener) 900 not tested/negstvybositive not tested/negstvybositive	not tested/negative/ not tested/negative/ not tested/negative/	s bolitive not teste bolitive not teste	227 21/mgative/positive dringative/positive	glomerulonsphrifi 93126 f f f f f f f f f f f f f f f f f f f	Polyateritis nodosa 767 not tested/normal/low/sector/ tested/normal/low/sector/ tested/normal/low/sector/ tested/negative/positive on tested/negative/positive t tested/negative/positive	117 tested/negative/ic tested/negative/ic					
amandan Marka Marka Marka Sam Cali Bala Marka Cali Cali Cali Cali Cali Cali Cali Cal	Ingnosis Information Informat	polymetilik (Wegener) 900 not tested/negstvybositive not tested/negstvybositive	not tested/negative/ not tested/negative/ not tested/negative/	s bolitive not teste bolitive not teste	227 21/mgative/positive dringative/positive	glomerulonsphrifi 93126 f f f f f f f f f f f f f f f f f f f	Polyateritis nodosa 767 not tested/normal/low/sector/ tested/normal/low/sector/ tested/normal/low/sector/ tested/negative/positive on tested/negative/positive t tested/negative/positive	117 tested/negative/ic tested/negative/ic					
In tested/negative/positive on tested/negative/positive on tested/negative/positive on tested/negative/positive	Ingnosis Trphacofe arum C3 arum C4 arum C4 arum C4 DDA DDA DDA AN AN AN AN AN AN AN AN AN A	polymetilik (Wegener) 900 not tested/negstvybositive not tested/negstvybositive	not tested/negative/ not tested/negative/ not tested/negative/	s bolitive not teste bolitive not teste	227 21/mgative/positive dringative/positive	glomerulonsphrifi 93126 f f f f f f f f f f f f f f f f f f f	Polyateritis nodosa 767 not tested/normal/low/sector/ tested/normal/low/sector/ tested/normal/low/sector/ tested/negative/positive on tested/negative/positive t tested/negative/positive	117 tested/negative/ic tested/negative/ic					
HRNA polymerase II 550 Mar GBM not tested/ngative/positive not tested/ngative/positive not tested/ngative/positive gBmbinn	Ingnosis arphacode arum C3 arum C3 arum C4 arum C4 arum C4 arum C4 arum C4 arum C4 belta2 Glycoprotein (gr arum C4 arum C4 belta2 Glycoprotein (gr arum C4 arum C4 arum C4 belta2 Glycoprotein (gr arum C4 arum C	polymetilik (Wegener) 900 not tested/negstvybositive not tested/negstvybositive	not tested/negative/ not tested/negative/ not tested/negative/	s bolitive not teste bolitive not teste	227 21/mgative/positive dringative/positive	glomerulonsphrifi 93126 f f f f f f f f f f f f f f f f f f f	Polyateritis nodosa 767 not tested/normal/low/sector/ tested/normal/low/sector/ tested/normal/low/sector/ tested/negative/positive on tested/negative/positive t tested/negative/positive	117 tested/negative/ic tested/negative/ic					
SM SM Compared	Ingnosis Trphacofe arum C3 arum C4 arum C4 arum C4 DDA DDA DDA AN AN AN AN AN AN AN AN AN A	polymetilik (Wegener) 900 not tested/negstvybositive not tested/negstvybositive	not tested/negative/ not tested/negative/ not tested/negative/	s bolitive not teste bolitive not teste	227 21/mgative/positive dringative/positive	glomerulonsphrifi 93126 f f f f f f f f f f f f f f f f f f f	Polyateritis nodosa 767 not tested/normal/low/sector/ tested/normal/low/sector/ tested/normal/low/sector/ tested/negative/positive on tested/negative/positive t tested/negative/positive	117 tested/negative/ic tested/negative/ic					
HIN2 Fille GBM not tested/negative/positive not tested/negative/positive gbalain	Ingnosis Ingnosis Ingnosis Ingno Cl Ingno	polymetilik (Wegener) 900 not tested/negstvybositive not tested/negstvybositive	not tested/negative/ not tested/negative/ not tested/negative/	s bolitive not teste bolitive not teste	227 21/mgative/positive dringative/positive	glomerulonsphrifi 93126 f f f f f f f f f f f f f f f f f f f	Polyateritis nodosa 767 not tested/normal/low/sector/ tested/normal/low/sector/ tested/normal/low/sector/ tested/negative/positive on tested/negative/positive t tested/negative/positive	117 tested/negative/ic tested/negative/ic					
not tastal/ngstre/positive in ot tastal/ngstr	Ingnosis arum C3 arum C3 arum C4 arum C4 arum C4 arum C4 arum C4 arum C4 arum C4 belta D4 D4 D4 D4 belta D4 D4 D4 D4 D4 D4 D4 D4 D4 D4	polymetilik (Wegener) 900 not tested/negstvybositive not tested/negstvybositive	not tested/negative/ not tested/negative/ not tested/negative/	s bolitive not teste bolitive not teste	227 21/mgative/positive dringative/positive	glomerulonsphrifi 93126 f f f f f f f f f f f f f f f f f f f	Polyateritis nodosa 767 not tested/normal/low/sector/ tested/normal/low/sector/ tested/normal/low/sector/ tested/negative/positive on tested/negative/positive t tested/negative/positive	117 tested/negative/ic tested/negative/ic					
opobulin	agnosis phacode phacode num C3 num C4	polymetilik (Wegener) 900 not tested/negstvybositive not tested/negstvybositive	not tested/negative/ not tested/negative/ not tested/negative/	s bolitive not teste bolitive not teste	227 21/mgative/positive dringative/positive	glomerulonsphrifi 93126 f f f f f f f f f f f f f f f f f f f	Polyateritis nodosa 767 not tested/normal/low/sector/ tested/normal/low/sector/ tested/normal/low/sector/ tested/negative/positive on tested/negative/positive t tested/negative/positive	117 tested/negative/ic tested/negative/ic					
	genosis phacode phacode urum C3 urum C4 urum C4 beta2 Glycoprotein lgt beta9	polynegilik (Wegener) 900 not testel/negstve/positive not testel/negstve/positive not testel/negstve/positive not testel/negstve/positive	not tested/negative/ not tested/negative/ not tested/negative/	boolitive not teste	227 sl/negative/jositive dinegative/jositive dinegative/jositive dinegative/jositive	giomenolonghittia	Polyanteritis nodesa 267 el to tested/normal/Acu/élevated tested/negative/positive tested/negative/positive tested/negative/positive tested/negative/positive tested/negative/positive tested/negative/positive	117 tested/negative/ic tested/negative/ic					
	genosis phacode num C3 num C3 num C4	polynegilik (Wegener) 900 not testel/negstve/positive not testel/negstve/positive not testel/negstve/positive not testel/negstve/positive	not tested/negative/ not tested/negative/ not tested/negative/	boolitive not teste	227 sl/negative/jositive dinegative/jositive dinegative/jositive dinegative/jositive	giomenolonghittia	Polyanteritis nodesa 267 el to tested/normal/Acu/élevated tested/negative/positive tested/negative/positive tested/negative/positive tested/negative/positive tested/negative/positive tested/negative/positive	117 tested/negative/ic tested/negative/ic					



Tubulopathies:

Shigatoxin PCR

STEC stool culture

	В	C	D		
Diagnosis	Auto-immune distal renal tubular acidosis	Sjögren disease	TINU Syndrome		
Orphacode	9999994	289390	91500		
Serum C3	not tested/normal/low	not tested/normal/low			
Serum C4	not tested/normal/low/elevated	not tested/normal/low/elevated			
Serum IgA					
dsDNA	not tested/negative/positive				
ANA	not tested/negative/positive	not tested/negative/positive	not tested/negative/positive		
anti-Ro (SSA)	not tested/negative/positive	not tested/negative/positive			
anti-RNP	not tested/negative/positive				
Anti-phospholipase A2					
antiphospholipid antibodies	not tested/negative/positive				
anti-CCP					
RF		not tested/negative/positive	not tested/negative/positive		
ACA					
cANCA					
pANCA			not tested/negative/positive		
myeloperoxidase-ANCA					
antiproteinase 3-ANCA					
PLA2 antibodies					
C3 nephritis factor					
CFH autoantibodies					
Anti-scl70					
anti PM-Scl					
Anti-RNA polimerasis III Anti-Mi-2					
anti-PR3					
Ati-GBM anti-PR3 Cryoglobulin Anti-Jo-1					
anti-PR3 Cryoglobulin			9		
anti-PR3 Cryoglobulin Anti-Jo-1	в	с		E	F
anti-PR3 Cryoglobulin Anti-Jo-1 MA: A Diagnosis	8 Infection-related hemolytic uremic syndro		D fethylmalonic acidemia with homocystinuria, type cb		F Thrombotic thrombocytopenic pu
anti-PR3 Cryoglobulin Anti-Jo-1 MA: A Diagnosis	-				54057
anti-PR3 Cryoglobulin Anti-Jo-1 A A Diagnosis Orphacode	Infection-related hemolytic uremic syndro	ne Atypical HUS	lethylmalonic acidemia with homocystinuria, type cb	Hemolytic uremic syndrome with DGKE deficiency	
anti-PR3 Cryoglobulin Anti-Jo-1 A A Diagnosis Diagnosis Serum C3	Infection-related hemolytic uremic syndro 54448	ne Atypical HUS 2134	fethylmalonic acidemia with homocystinuria, type cb 79282 not tested/normal/low	Hemolytic uremic syndrome with DGKE deficiency 357008	54057 not tested/normal/low
Anti-PR3 Crycglobulin Anti-Jo-1 MA: Diagnosis Orphacode Serum C3 Serum C4	Infection-related hemolytic uremic syndro 54448 not tested/normal/low	ne Atypical HUS 2134 not tested/normal/low	fethylmalonic acidemia with homocystinuria, type cb 79282 not tested/normal/low	Hemolytic uremic syndrome with DGKE deficiency 357008 not tested/normal/low	54057 not tested/normal/low
Anti-PR3 Crycglobulin Anti-Jo-1 A Diagnosis Orphacode Serum C3 Serum C4 Serum C4	Infection-related hemolytic uremic syndro 54448 not tested/normal/low	ne Atypical HUS 2134 not tested/normal/low	fethylmalonic acidemia with homocystinuria, type cb 79282 not tested/normal/low	Hemolytic uremic syndrome with DGKE deficiency 357008 not tested/normal/low	54057 not tested/normal/low
anti-PR3 Crycglobulin Anti-Jo-1 MA: A Diagnosis Orphacode Serum G3 Serum G3 serum G4 anti-dsDNA antibodies anti-nuclear antibodies (ANA)	Infection-related hemolytic uremic syndro 54448 not tested/normal/low	ne Atypical HUS 2134 not tested/normal/low	fethylmalonic acidemia with homocystinuria, type cb 79282 not tested/normal/low	Hemolytic uremic syndrome with DGKE deficiency 357008 not tested/normal/low	
anti-PR3 Cryoglobulin Anti-Jo-1 MA: Diagnosis Orphacode Serum C3 Serum C4 anti-dsDNA antibodies anti-dsDNA antibodies (ANA) anti-Ro (SSA)	Infection-related hemolytic uremic syndro 54448 not tested/normal/low	ne Atypical HUS 2134 not tested/normal/low	fethylmalonic acidemia with homocystinuria, type cb 79282 not tested/normal/low	Hemolytic uremic syndrome with DGKE deficiency 357008 not tested/normal/low	54057 not tested/normal/low
anti-PR3 Cryoglobulin Anti-Jo-1 Anti-Jo-1 A Diagnosis Dryhacode Serum C4 Serum C4 Inti-SoNA antibodies Inti nuclear antibodies (ANA) anti-Rop (SSA) Inti-RNP	Infection-related hemolytic uremic syndro 54448 not tested/normal/low	ne Atypical HUS 2134 not tested/normal/low	fethylmalonic acidemia with homocystinuria, type cb 79282 not tested/normal/low	Hemolytic uremic syndrome with DGKE deficiency 357008 not tested/normal/low	54057 not tested/normal/low
Anti-PR3 Crycglobulin Anti-Jo-1 Anti-Jo-1 Anti-Jo-N Jagnosis Orphacode Serum C3 Serum C3 Anti-dsNA antibodies Anti-dsNA antibodies Anti-dsNA antibodies Anti-RNP Anti-phospholipase A2	Infection-related hemolytic uremic syndro 54448 not tested/normal/low	ne Atypical HUS 2134 not tested/normal/low	fethylmalonic acidemia with homocystinuria, type cb 79282 not tested/normal/low	Hemolytic uremic syndrome with DGKE deficiency 357008 not tested/normal/low	54057 not tested/normal/low
Anti-PR3 Cryoglobulin Anti-Jo-1 Anti-Jo-1 A Diagnosis Orphacode Serum C3 Serum C3 Serum C3 Serum C4 Serum C4 Anti-JoDNA antibodies Anti-Ro (SSA) anti-Ro (SSA) anti-Ro PSA Anti-Johospholipase A2 Anti-Johospholipal antibodies	Infection-related hemolytic uremic syndro 54448 not tested/normal/low	ne Atypical HUS 2134 not tested/normal/low	fethylmalonic acidemia with homocystinuria, type cb 79282 not tested/normal/low	Hemolytic uremic syndrome with DGKE deficiency 357008 not tested/normal/low	54057 not tested/normal/low
Anti-PR3 Crycglobulin Anti-Jo-1 Anti-Jo-1 Anti-Jo-1 Anti-Jone Serum C4 Serum C3 Serum C4 Serum C4 Anti-Apoly Antibodies Anti-Apoly Antibodies Anti-Apoly Antibodies Anti-Apoly Antibodies Anti-Apoly Antibodies Anti-Apoly Antibodies Anti-Apoly Antibodies Ca nephritis factor	Infection-related hemolytic uremic syndro 54448 not tested/normal/low not tested/normal/low/elevated	ne Atypical HUS 2134 not tested/normal/low not tested/normal/low/elevated	Rethylmalonic acidemia with homocystinuria, type cb 79282 not tested/normal/low d not tested/normal/low/elevated	Hemolytic uremic syndrome with DGKE deficiency 357008 not tested/normal/low not tested/normal/low/elevated	54057 not tested/normal/low/ not tested/normal/low/eleva
anti-PR3 Cryeglobulin Anti-Jo-1 Anti-Jo-1 Anti-Jo-2 Anti-Anti-Anti-Anti-Anti-Anti-Anti-Anti-	Infection-related hemolytic uremic syndro 54448 not tested/normal/low	ne Atypical HUS 2134 not tested/normal/low	fethylmalonic acidemia with homocystinuria, type cb 79282 not tested/normal/low	Hemolytic uremic syndrome with DGKE deficiency 357008 not tested/normal/low	54057 not tested/normal/low

<u>Imaging:</u> Diagnostic imaging describes various techniques of viewing the inside of the body to help figure out the causes of an illness and confirm a diagnosis. For example, Fetal Posterior Urethral Valves (PUV) are usually detected in a fetus during pregnancy thanks ultrasounds diagnostic or MRI.

not tested/negative

not tested/negative

not tested/r

not tested/negative

not tested/negative

not tested/negati

ot tested/negative/positive

not tested/negative/positive

not tested/negative/positiv

not tested/negative

not tested/negative

not tested/negative

not tested/negative

not tested/negativ

A <u>kidney biopsy</u> involves taking one or more tiny pieces (samples) of kidney to look at with special microscopes. The microscopes make it possible to see the samples in greater detail. This investigation is important in the differential diagnosis of glomerulopathies.

A <u>skin biopsy</u> is used to diagnose or rule out skin conditions and diseases. It may also be used to remove skin lesions. This investigation is important to perform in diseases involving kidney and skin like Alport Syndrome or Granulomatosis with polyangiitis.

<u>Genetic screening</u> is a type of medical test that identifies changes in chromosomes, genes, or proteins. The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a person's chance of developing or passing on a genetic disorder. If you do not have yet the results of this test, please click on "pending". You will have the opportunity to enter the results any time!!!

By Other methodologies we mean all analyses that do not include those mentioned above.



21. How can I choose between the different Methods of genetic diagnostics?

There are different methods to perform a genetic diagnostic.

<u>Individual gene testing</u>: Single gene testing is performed to identify changes or variants in a single gene. Basically, when we have a suspect of a disease, for most of the diseases we already know on which gene we could find the mutation. We expect that the mutation is located in that single gene and the investigator test just that single one.

<u>NGS panel screening</u>: The next generation sequencing techniques is the targeted enrichment step where gene panels focus on a limited number of genes. We expect that the mutation is possibly located on 2 or 3 different genes which are usually involved in that disease and we test just these ones.

<u>Exome sequencing</u>: Exome sequencing, also known as whole exome sequencing (WES), is a genomic technique for sequencing all the protein-coding regions of genes in a genome (known as the exome). The goal of this approach is to identify genetic variants that alter protein sequences, and to do this at a much lower cost than whole-genome sequencing. This is a untargeted method and is usually used when the investigator has not idea which gene could be affected.

Nowadays the most used methods are the NGS gene panel screening together the individual gene testing.

Genetic diagnostics for primary renal diagn	osis				
Date of screening (leave field empty if unknown)	(dd/mm/yyyy)				
Was a causative gene abnormality identified?	Yes 🗸				
Receipt date of genetic results	(dd/mm/yyyy)				
Please fill in the fields above and save first. Genetic data depends on the diagnosis.					
Methods	 Individual gene testing NGS gene panel screening Exome sequencing 				
Further comments on genetics					

22. How do I enter the genetic results?

When you have identified a causative gene mutation, you will be asked to enter the details. Depending on the selected diagnosis, only associated genes will appear in the dropdown list. Please choose the inheritance, the affected gene and the zygosity.

For the mutation you will be asked to enter the coding DNA sequence change (\rightarrow c.). This is a mandatory field. Information on the amino acid sequence change (\rightarrow p.) and the Gen Bank cDNA reference sequence (\rightarrow NM_) are optional.

If you are unsure, please consult the treating clinician or the geneticist.



Inheritance	Affected gene	Zygosity	т	Mutation (e.g. c.123A>G, p.Arg123His, NM_000123.4) Type of variant (c.) : >, del, dup, inv, ins, delins			
AR	NPHS1 \sim	Homozygous	c p		Mandatory field Optional field		
			Ν	MM_	Optional field		
Further comm	nents on genetics						

23. What to do if my gene is not in the dropdown list

It might happen that new gene mutations have been identified, which are not yet in our list. Please contact us at <u>erkreg@erknet.org</u> to check whether we can add this to the database.

24. What should I indicate when the genetic diagnostic has not been performed?

You should not check "Genetic Screening" under "How was the diagnosis established?". This information may possibly be added in the future if the test should be performed at a later stage.

25. How to enter CAKUT patient?

- ✓ All syndromic CAKUT
- ✓ All familial CAKUT
- ✓ All CAKUT cases with impaired renal mass, as evidenced by CKD stage 2 and higher and/or bilateral renal parenchyma abnormalities on ultrasound (hypo/dysplasia, hyperecogenicity)
- ✓ Single kidney (unilateral renal agenesis) with associated anomaly (hypodysplasia and/or urinary tract abnormality) of existing kidney
- Cystic-multidysplastic kidney with associated anomaly (hypodysplasia and/or urinary tract abnormality) of contralateral kidney (hypertrophic kidney as single symptom)
- ✓ Bilateral VUR 4 or 5 → no unilateral
- ✓ Posterior urethral valves and all other Lower Urinary Tract Obstruction (LUTO)
- ✓ For CAKUT patient ≤2 years information on ultrasound diagnostics is mandatory to fill in

Renal agenesis, unilateral & unilateral multicystic dysplastic kidney


→These patients will have "two renal diagnoses": please, indicate as first "renal agenesis unilateral" and a second diagnosis to indicate the associated anomaly of the existing kidney (e.g. "hypodysplasia" or "VUR")

26. How to enter syndromic CAKUT patients

- ✓ Enter the renal phenotype as primary renal diagnosis first
- ✓ Upon saving the entry, you will be asked whether the diagnosis is part of a syndromic disorder
- \checkmark \rightarrow It is technically not possible to select a syndromic CAKUT disorder as primary renal diagnosis

Primary renal	diagnos	is		Renal dysplas	ia, bil	ateral (OC: 93173)		
Select diagnosis	OR Diag	gnosis by gene	OR	Enter OrphaCode	OR	Search diagnosis name		
Syndromic disord	der?	Cat-eye syno	drome)				$\overline{}$
Further specification	tions]	





27. How do I choose the date of the "initial visit"?

The date of the initial visit of a registry patient may coincide with the date of the signature of the informed consent but cannot be more than six weeks prior to the date of the informed consent.

28. How do I know when the next visit is due?

The date of the next visit to be documented is indicated in the patient dashboard.

29. Why is "next visit due" highlighted in different colors?

The statement "next visit due" can be highlighted in different colors depending on the status of the registration. Green means that the patient has been correctly saved in the system. Yellow means that the patient has been saved correctly but needs to be updated or has missing data. Red means that the initial visit of the patient has not been entered yet.



30. When do I have to terminate a patient and how can I do it?

	500-0028 P M-11/2021 Tubulopathy Basic data Add visit Termination Previous visits: 2	CKD5 Next visit due: 24/04/2023 🗱
Patient-ID Reason for end of fol	500-0028	 Patient initially entered with a non-established diagnosis final results proved to be not a rare kidney disease loss of follow-up → other
Reason for end of fol Date Reason for loss of fo	(dd/mm/yyyy)	 A patient not seen in the centre for 5(?) years? Patient death Transition to other centre

31. What is the medication and therapy database?

For some diagnoses (cystinosis, aHUS, cystinuria, pediatric SLE) we are collecting the medication history and information and extracorporeal therapies.

Marchane /	Patient 500-0030 (M-10/1973)	
500-0030 A M-10/1973 Metabolic nephropathy Basic data Add visit Termination Previous visits: Medications Extracorp. Therapies	Medication history = ongoing medication = terminated medication Medication Start date Single dose Frequency = dose/ligitory Start date Single dose Frequency = dose/ligitory Start date Single dose Frequency = dose/ligitory Start date Single dose	
Patient 500-0030 (M-10/1973) Medication Natory environment medication environment medication Citic on a medication to edit f (add medication) Apress actions any other metication Apress actions any other metication Participation Rest Society agents Activity personnels Rest Society agents Activity personnels Hydrocortisione Immunohagpressents Coloniduzamab Chinukazumab Chinukazumab Chystaamin (Phocybol) Enzyme regladement theragu Agalitidese beta (Fabrazyme) Enzyme regladement theragu Enzyme regladement theragu Agalitidese beta (Fabrazyme) Enzyme regladement theragu Agalitidese beta (Fabrazyme) Enzyme regladement theragu Enzyme re	Start date 01012001 311122001 Click on a medication to the list please contact tanja whotkewski@med.uni-heldelberg.de. Medication Medication Medication Againidase beta (Fabrazyme) Start date Therapy history Leve and Close Therapy history Save and Close • explain detaining Click on a herapy to edit of (Add therapy) Note: If you cannot find the merge Start date Click on a herapy to edit of (Add therapy) Note: If you cannot find the there Real replacement therapy Divid of the tarpy Start date Click on a herapy to edit of (Add therapy) Note: If you cannot find the there Real replacement therapy Description Plasmapheresis	

32. What "ID number" should I indicate in the informed consent?

This space must be completed with the automatically generated system patient ID once the patient has been successfully registered.



33. What is the Key Performance Indicator (KPI) Monitoring System

To harmonize patient care across Europes, ERKNet expert centres agreed to adhere to endorsed clinical practice guidelines with respect to diagnostics and treatment of rare kidney diseases. The KPI system allows to monitor the guideline adherence and patient management in those centres.

In addition to basic information, some disease-specific data elements will be asked in ERKReg to measure the KPIs. Each centre has continuous access to its own performance statistics via the ERKReg website. In addition, KPI reports are sent out twice per year to all centres.

KPI Monitoring General Glomerulopathies					Key Performance Ind Heidelberg, Univers pediatric nephrol	icator Monitoria
Tubulopathies & meta nephropathies	KPI Monitoring: General					
Thrombotic microang						1/2021
Structural kidney disc	Γ	Pediatr	ic patients	Adult	patients	-021
CAKUT, Ciliopathies	-					
Pediatric CKD		Your center	All ERKNet centers	Your center	All ERKNet centers	
Pediatric Dialysis Pediatric Transplanta	Time (months) from 1 st symptom to diagnosis: Median (IQR)	2.6 (0.8 - 7.0) (n = 608)	1.4 (0.5 - 6.5) (n = 6825)	() 	2.8 (0.7 - 18.2) (n = 2938)	
	Time (months) from referral to diagnosis: Median (IQR)	0.3 (0.0 - 2.8) (n = 451)	0.2 (0.0 - 3.6) (n = 5609)	() 	0.2 (0.0 - 3.0) (n = 2451)	ey performance indicators (newspanise lange) or surreavy statistics of al
	% hereditary disease patients with any genetic screening	73.1 % (207/283)	62.1 % (2452/3951)		42.1 % (1241/2951)	hold live to propere
	% hereditary disease patients with NGS screening (panel, WES)	70.0 % (198/283)	38.5 % (1523/3951)		30.8 % (910/2951)	

34. How can I contact the IT support?

In case you have any technical difficulty logging into the ERKReg or using any of its functions, please contact the support team via email <u>erkreg@erknet.org</u>. Please sendyour feedback, suggestions, or complaints to the support team.